Loading
Liver Disease Diagnosis and Treatment · Journal article
Arthritis Care & Research · September 7, 2026
Encouraging direction, but not yet definitive.
In 150 gout patients starting allopurinol with normal baseline transaminases, 20% developed mild asymptomatic liver enzyme elevation during median 33.5 weeks follow-up. Escalation or continuation of allopurinol in those with elevated enzymes was safe: the majority remained stable, improved, or resolved without worsening, and higher allopurinol dose was not independently associated with enzyme elevation.
Prospective observational cohort study. Gout patients with normal baseline serum aminotransferases initiated on allopurinol. Mean age 56.6 years, 95.3% male. Comorbidities included alcohol use (21.5%), obesity (28.9%), and metabolic dysfunction-associated steatotic liver disease (7.3%).. Intervention: Allopurinol initiated and escalated as tolerated; dose escalation continued in patients with mild-moderate transaminase elevation.. n = 150.
30 out of 150 patients (20.0%) developed raised AST/ALT during follow-up Majority of elevation was mild (86.7%), none were severe 18 out of 19 patients with raised transaminases at Visit-2 had allopurinol maintained or increased; none experienced worsening AST/ALT at subsequent visit
Short median follow-up (33.5 weeks); longer-term safety beyond ~1 year not reported.
The findings suggest that clinicians need not interrupt or avoid escalating allopurinol dose when mild asymptomatic transaminase elevation occurs, provided it is monitored. Alcohol consumption should prompt closer surveillance, and statin use may be protective.
A prospective observational cohort showing that mild transaminase elevation during allopurinol therapy does not worsen and does not require dose interruption; sound method but limited by single-centre design, lack of control group, and modest sample size.
As stated by the source record.
Quoted from the source exactly as published.
The findings suggest that clinicians need not interrupt or avoid escalating allopurinol dose when mild asymptomatic transaminase elevation occurs, provided it is monitored. Alcohol consumption should prompt closer surveillance, and statin use may be protective.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
OBJECTIVE: Routine liver enzyme monitoring is advocated while on allopurinol but supporting guidance is lacking. We assessed the incidence and factors associated with elevated liver enzymes in gout patients commenced on allopurinol. METHODS: 150 patients with gout and normal baseline serum aminotransferases initiated on allopurinol were followed prospectively over three visits. Raised transaminases were defined as mild, moderate or severe if AST or ALT was raised <2, 2-3 or >3 times above upper normal limits, respectively. Predictors of AST/ALT elevation were assessed using Generalized Estimating Equations. RESULTS: Mean age was 56.6 years, 95.3% were men. Median follow-up was 33.5(IQR 22.8-53.1) weeks. 32(21.5%) drank alcohol, 43(28.9%) were obese and 11(7.3%) had metabolic dysfunction-associated steatotic liver disease. 30(20.0%) developed raised AST/ALT during follow-up, majority (86.7%) was mild while none were severe. Allopurinol was maintained or increased in 18 out of 19 patients with raised serum aminotransferases at Visit-2. Their elevated AST/ALT remained stable (27.8%), improved (11.1%) or resolved (33.3%) at subsequent visit. None had worsening AST/ALT. Multivariate analysis revealed that alcohol consumption (adjusted OR 3.52, 95%CI 1.41-8.79) and statin non-user (adjusted OR 3.41, 95%CI 1.04-11.17) were independent predictors of raised transaminases. Higher allopurinol dose was not associated with development of liver enzyme elevation (p=0.193). CONCLUSION: Mild asymptomatic AST/ALT elevation is common among gout patients and is not influenced by allopurinol dose escalation. Alcohol consumption was an independent risk factor for elevated liver enzymes while statin use appeared protective. Allopurinol can be safely escalated despite mild-moderate serum aminotransferase elevation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.